NYU Cardiology is having a major presence at the AHA Scientific Sessions and everyone came out to celebrate Judith Hochman receiving the Research Achievement Award.

Brilliant presentation by @SripalBangalore on the TUXEDO-2 study. Ticagrelor failed to meet non-inferiority in patients with diabetes mellitus and multivessel coronary disease. Prasugrel emerges as the most effective therapeutic option in this group of patients. #LaSECteLleva a #AHA25

And @SripalBangalore sharing thoughts about ECMO and thrombectomy. #PERSEVERE is ongoing

Why should one accept 1M dual therapy to be up to twice as worse as 12M dual therapy for ischemic outcomes?

No benefit from beta-blockers in patients with recent myocardial infarction and LVEF equal or greater than 50%. #AHA2025 IPD meta-analysis of 5 RCTs including 17,801 patients (REBOOT, REDUCE-AMI, BETAMI, DANBLOCK, and CAPITAL-RCT). @Borjaibanez1 @dan_atar @RosselloXavier @evaprescott @drjohnm @mmamas1973 @djc795 @mirvatalasnag @EAPCIPresident @SABOURETCardio @Hragy @kaulcsmc @EricSecemskyMD @venkmurthy @DrMarthaGulati @SripalBangalore @sbrugaletta @DLBHATTMD @EricTopol @CMichaelGibson @DFCapodanno @nadig_cardio @Ortega_Paz @HadyLichaaMD @ACCinTouch @Medscape @AHAScience Published on @NEJM nejm.org/doi/full/10.1056/NE…

Shock 2.0: The Next Wave of Innovations in Cardiogenic Shock. @AHAScience @SripalBangalore

📢 Calling all #FITs and #EarlyCareer cardiologists!  Join leading experts Drs. @gregorymmarcus, @SripalBangalore and @PassmanRod for “Mastering Research and Writing in Cardiology: The Physician-Scientist’s Guide to Success.”  🗓 Sat, Nov 8 | 1:30–2:45 PM  📍 #AHA25

#AHA25 is this weekend ❤️‍🔥 Stay tuned for Late Breaker Discussions with Dr @hvanspall as she talks with investigators about study design, data, and interpretation. Featuring Drs @SripalBangalore, @EBohula, @ProfSNicholls, Dodson & Van’t Hof. #CardioTwitter #Cardiology

Even after the 👻 are gone, one nightmare still haunts cath labs: entrapped gear The Oct @SCAI QI Tip is on stuck wires, burrs, balloons & stents. Don’t get spooked: scai.org/quality-improvement… @kevinjamescroce @SripalBangalore @SandeepNathanMD @SrihariNaiduMD @PinakShahMD

Now published! Milestone-based post-PCI discharge pathway reduces LOS without increased adverse events. Led by star @nyulangone CV fellow Dr. Johanna Lerner Same obs period for all PCI pts is a thing of the past ahajournals.org/doi/full/10.…

5/ The case presented- a 53 yo asymptomatic with severe mid LAD, confirmed on angio FFR and IVUS, ultimately underwent PCI with IVI guidance and got excellent results. What do we tell the patient the benefit of PCI in his case? #TCT2025 @realarainmd

4/. Is there a clinical outcomes benefit of Revascularization in patients with asymptomatic ischemic? Please stay tuned. I will be presenting the latest data from ISCHEMIA tomorrow. @glennfishman @nyulangone

@realarainmd @nyheartdoc @adityadoc1 @DFCapodanno @ColletCarlos @abadkhan2002 @purviparwani @evandrofilhobr @vicentejmzmd @HadyLichaaMD

2/. What would your approach be?

1/ Asymptomatic patient with high CAC and CTA with severe 2VD including prox LAD. What should be the approach? @SVRaoMD speaking about idealized heart team approach. #TCT2025 @nyulangone @glennfishman

NYU Langone Presenter: Dr. Sripal Bangalore (@sripalbangalore)  📅 Saturday, Oct. 27th  Topic: Invasive vs. Conservative Management in Patients with Asymptomatic Ischemia: ISCHEMIA Trial 🕑 3-4PM  📍 Station 8 | Halls B-C | Exhibition Level | Moscone South  #TCT2025 #NYULangone

Save the date! Join @ImpCare_Vasc at #TCT2025 for a Lunch Symposium on 10/28 at 12:15 PM. Hear Dr. @SripalBangalore & Dr. Mahesh Raju share key insights from the SYMPHONY-PE Trial and explore Symphony’s real-world impact. Add to calendar: bit.ly/4niiVnp #VTE | #ad

Save the date! Join @ImpCare_Vasc at #TCT2025 for a Lunch Symposium on 10/28 at 12:15 PM. Hear Dr. @SripalBangalore & Dr. Mahesh Raju share key insights from the SYMPHONY-PE Trial and explore Symphony’s real-world impact. Add to calendar: bit.ly/4niiVnp #VTE | #ad

#TCT2025: Interested in learning about the latest data and innovation in PE thrombectomy? Don’t miss these presentations from Dr. @SripalBangalore, who will share findings from two analyses of the SYMPHONY-PE Trial, and Dr. John Moriarty (@JonnyMoriarty), who will discuss emerging devices for catheter intervention, including our Vascular technologies. More details 👇 #PulmonaryEmbolism #VTE #Thrombectomy Rx only. ISI: bit.ly/3pAaUlw

Great discussion on Percutaneous therapies for PE and Endocarditis at #CVSF. Excited for the future. @angiodynamics @sanjum @StephanieYounes @MarqPatton @glennfishman @SVRaoMD @BrentKeeling @AlexandraLansky